# LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

> **NCT01828112** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 231 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Ceritinib
- **DRUG:** Pemetrexed
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01828112
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-28
- **Primary completion:** 2016-01-26
- **Final completion:** 2023-11-10
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01828112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01828112, "LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01828112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*